Inhibition of GATA2 in prostate cancer by a clinically available small molecule

Castration-resistant prostate cancer (CRPC) remains highly lethal and in need of novel, actionable therapeutic targets. The pioneer factor GATA2 is a significant prostate cancer (PC) driver and is linked to poor prognosis. GATA2 directly promotes androgen receptor (AR) gene expression (both full-len...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaochar, Salma, Rusin, Aleksandra, Foley, Christopher, Rajapakshe, Kimal, Robertson, Matthew, Skapura, Darlene, Mason, Cammy, Berman De Ruiz, Karen, Tyryshkin, Alexey Mikhailovich, Deng, Jenny, Shin, Jin Na, Fiskus, Warren, Dong, Jianrong, Huang, Shixia, Navone, Nora M, Davis, Christel M, Ehli, Erik A, Coarfa, Cristian, Mitsiades, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634153/
https://www.ncbi.nlm.nih.gov/pubmed/34636746
http://dx.doi.org/10.1530/ERC-21-0085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634153/
https://www.ncbi.nlm.nih.gov/pubmed/34636746
http://dx.doi.org/10.1530/ERC-21-0085

Ejemplares similares